FN2 Earnings Intelligence
Abbott Laboratories earnings overview
Latest Abbott Laboratories (ABT) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
Abbott Laboratories
Abbott's Q3 analysis supports a mixed view of the growth thesis: resilient comparable sales and a broad product pipeline support ongoing demand, while lower full-year revenue guidance and near-term electrophysiology and diabetes headwinds temper the outlook. The nutrition separation is the key strategic test for whether management can deliver the expected post-separation growth and margin benefits.
Abbott Laboratories
Abbott's Q2 2026 results mark a clear inflection from the prior quarter. Comparable sales growth accelerated to 4.8% (from 3.7% in Q1), and adjusted EPS of $1.31 beat the $1.28 consensus by 2.3%. Management raised full-year EPS guidance to $5.45–$5.60, reversing Q1's lowered posture. The market responded with an 11.3% abnormal move on 2.4x baseline volume, with continued upward drift since. The thesis now hinges on a second-half launch wave — Libre Duo, Amulet 360, Bolt 2.0, Tactiflex Duo, and new nutrition products — underpinned by Exact Sciences integration and a planned fifth billion-dollar sensor manufacturing facility.
Abbott Laboratories
The supplied analysis supports a mixed but constructive operating picture: device launches, Exact Sciences integration, Nutrition recovery and CGM opportunities provide growth support, while lowered guidance sentiment and execution questions temper the outlook.
Abbott Laboratories
The supplied analysis supports a constructive but qualified view: Abbott's device, diabetes-care and diagnostics pipeline can support growth, while nutrition weakness, China pricing pressure, tariffs and acquisition execution are important offsets.
Abbott Laboratories
The transcript analysis supports a constructive view of Abbott’s growth trajectory: medical devices and a broad new-product pipeline are offsetting pressure in China diagnostics and other challenged areas. The evidence for durability is strong but depends on product launches, CGM adoption, reimbursement, and the expected recovery in China diagnostic volumes.
Abbott Laboratories
The supplied analysis supports a mixed but constructive view: medical-device growth and a broad product pipeline provide evidence for durable demand, while diagnostic weakness, tariffs, China pricing, regulation, and CGM competition are important counterweights.
Abbott Laboratories
The supplied analysis supports a constructive but conditional view: Abbott’s nutrition and medical-device franchises, margin expansion, and product pipeline support continued growth, while tariffs, China pricing, regulatory timing, and weak COVID testing remain important tests.
Abbott Laboratories
The supplied analysis supports a constructive but execution-dependent view: Abbott's CGM and structural-heart franchises, product pipeline, and planned margin expansion provide growth support, while taxes, FX, competition, and launch execution remain material offsets.
Get the ABT recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.